California Lawyers Association

Inevitable Disclosures

Articles from the Intellectual Property Law Section’s eNews

On June 29, as a result of the recent Supreme Court decision in U.S. v. Arthrex, Inc., the USPTO implemented an interim procedure whereby review of a Patent Trial and Appeal Board (PTAB) final written decision in an inter partes, post-grant, or covered business method review may be initiated sua sponte by the Director or requested by a party to a PTAB proceeding. Read more
The USPTO is seeking comments from the public regarding the impact of patent eligibility jurisprudence in the United States since the Supreme Court’s 2016 decisions in Mayo and Alice and subsequent Federal Circuit decisions applying the Supreme Court’s legal framework. Read more
On May 18, the USPTO published a Notice of Proposed Rulemaking (NPRM) to implement changes to trademark rules of practice authorized by the Trademark Modernization Act (TMA) of 2020. Read more
The USPTO just recognized more than 100 patent practitioners for volunteering 50 or more hours on patent pro bono programs in 2020. Read more
On May 18, the USPTO published a Notice of Proposed Rulemaking (NPRM) to implement changes to trademark rules of practice authorized by the Trademark Modernization Act (TMA) of 2020. Read more
Santa Clara University School of Law is conducting a study to identify, understand, and provide actionable advice about the best practices for attracting and including diverse inventors in the invention and patenting process. Read more
A major piece of copyright legislation, the Copyright Alternative in Small-Claims Enforcement Act (CASE Act), was tucked into the omnibus spending and COVID-19 relief bill passed by Congress on December 21, 2020. Read more
This January the CLA IP Section is excited to be highlighting some of our most loved and most fascinating webinars from the past! Read more
Since we were unable to meet in person this year, the IP Section held its first ever Shelter In Place Institute. Read more
As of this writing, the United States Food and Drug Administration (“FDA”) has approved GW Pharma’s CBD drug Epidiolex for treating profound refractory pediatric epilepsy syndromes (Dravet syndrome and Lennox Gastaut syndrome) as well as for treating seizures associated with tuberous sclerosis complex (TSC) in patients one year of age or older. Read more

Forgot Password

Enter the email associated with you account. You will then receive a link in your inbox to reset your password.

Personal Information

Select Section(s)

CLA Membership is $99 and includes one section. Additional sections are $99 each.

Payment